此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer (MISO)

2026年11月6日 更新者:Qinglei Gao、Tongji Hospital

A Phase 2 Study of Mirvetuximab Soravtansine (MIRV) in Combination With Suvemcitug for the Treatment of Folate Receptor Alpha (FRα)-Expressing Partially Platinum-Sensitive Ovarian Cancer (MISO)

This is a prospective, single-arm, phase II study designed to evaluate the efficacy and safety of mirvetuximab soravtansine combined with suvemcitug in patients with FRα-positive partially platinum-sensitive recurrent ovarian cancer.

Approximately 80 patients will be enrolled. Eligible patients must have recurrent high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with FRα expression and disease recurrence occurring 6 to 12 months after completion of platinum-based chemotherapy.

Participants will receive mirvetuximab soravtansine and suvemcitug every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. Tumor response will be assessed according to RECIST version 1.1.

The primary objective is to evaluate the objective response rate (ORR). Secondary objectives include duration of response (DOR), progression-free survival (PFS), overall survival (OS), CA125 response, and safety outcomes. Exploratory analyses will assess the relationship between FRα expression, other biomarkers, and clinical outcomes.

研究概览

研究类型

介入性

注册 (估计的)

80

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Hubei
      • Wuhan、Hubei、中国、430030
        • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  1. Signed written informed consent and able to comply with the protocol-specified visits and related procedures.

  2. Female patients aged ≥18 years.

  3. Patients with histologically or cytologically confirmed high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

  4. Recurrence after prior standard platinum-based chemotherapy with or without bevacizumab ± PARP inhibitor, with the date of diagnosis of recurrence being 6-12 months from the last platinum-based chemotherapy.

  5. Patients with a BRCA mutation must have received PARP inhibitor therapy.

  6. Patients must have experienced disease progression during or after the most recent anticancer therapy received.

  7. Tumor FRα expression has been determined by the VENTANA FOLR1 assay to be ≥25% (requiring ≥25% of tumor cells with staining intensity ≥2+ after FRα staining).

  8. Patients must provide archived tumor tissue block or sections for central laboratory FRα testing and exploratory biomarker analysis. Tissue wax blocks are preferred; if wax blocks cannot be provided, no fewer than 10 unstained sections should be provided.

  9. Patients must have at least one evaluable lesion per RECIST v1.1 (determined by the investigator via imaging).

  10. Eastern Cooperative Oncology Group performance status (ECOG PS) must be 0-2.

  11. Patients must have received at least 1 but no more than 2 lines of prior systemic anticancer chemotherapy:

    1. Neoadjuvant therapy ± adjuvant therapy is considered as 1 line of therapy;
    2. A change in treatment due to toxicity in the absence of disease progression is considered part of the same line of therapy (i.e., not counted separately).
  12. Adequate major organ function, and the patient is considered by the investigator to be suitable for treatment with mirvetuximab soravtansine combined with suvemcitug, defined as:

    1. Absolute neutrophil count (ANC) ≥1.5 × 10^9/L (1,500/μL), and no use of G-CSF within the prior 10 days, or no use of long-acting WBC growth factors within the prior 20 days;
    2. Platelet count ≥100 × 10^9/L (100,000/μL) with no platelet transfusion within the prior 10 days;
    3. Hemoglobin ≥9.0 g/dL with no packed red blood cell (PRBC) transfusion within the prior 21 days;
    4. Serum creatinine ≤1.5 × upper limit of normal (ULN);
    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × ULN;
    6. Serum bilirubin ≤1.5 × ULN (patients with Gilbert's syndrome may be enrolled if total bilirubin <3.0 × ULN);
    7. Serum albumin ≥2 g/dL.
  13. All toxicities related to prior treatment (except alopecia) must have recovered to ≤ Grade 1 per CTCAE v5.0.

  14. Any major surgery the patient has undergone must have been completed at least 4 weeks prior to the first dose of mirvetuximab soravtansine and suvemcitug, and postoperative complications from prior surgical treatment must have resolved or be stable.

  15. The subject's life expectancy is assessed by the investigator to be at least 12 weeks.

Exclusion Criteria:

  1. Concurrent participation in another clinical study.
  2. Patients with endometrioid, clear cell, mucinous, or sarcoma histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian tumors.
  3. Patients whom the investigator considers to have other serious systemic diseases (including active infection, non-infectious interstitial lung disease, clinically significant cardiovascular or cerebrovascular disease within 6 months prior to the first dose, etc.) or other reasons that make them unsuitable for participation in this clinical study.
  4. Known prior hypersensitivity to monoclonal antibody therapy or maytansinoids, or to the study drug and/or any of its excipients.
  5. Patients with active or chronic corneal disease, history of corneal transplant, or active eye disease requiring continuous treatment/monitoring, for example: uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injection therapy, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision.
  6. Patients with pleural effusion, pericardial effusion, or ascites that cannot be controlled by drainage or other methods should be excluded, except for small amounts of fluid that are asymptomatic or do not require clinical intervention.
  7. Patients who have previously received mirvetuximab soravtansine or other FRα-targeted therapies.
  8. Known active central nervous system (CNS) metastases and/or leptomeningeal disease. Subjects with untreated but asymptomatic brain metastases, or those with imaging evidence of sustained progression-free status for at least 4 weeks after treatment and no need for hormones or anti-epileptic therapy for at least 2 weeks, may be considered for enrollment.
  9. Pregnant or breastfeeding women. Women of childbearing potential must agree to take highly effective contraceptive measures during the study drug period and for at least 7 months after the last dose of study drug. Women of childbearing potential are defined as fertile women from menarche until menopause, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.
  10. Patients who have received anti-tumor therapy or participated in a clinical study and received an investigational drug within 2 weeks prior to the first dose of this study.
  11. Patients with hypertension that cannot be reduced to the normal range with antihypertensive medication (systolic blood pressure > 150 mmHg, diastolic blood pressure > 90 mmHg).
  12. Patients with NYHA Class III-IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) < 50% as indicated by echocardiography
  13. Patients with proteinuria (urine protein > 1+ found during screening; or urine protein 1+ that does not return to normal upon repeat testing within 24 hours);
  14. Patients with a clear tendency for gastrointestinal bleeding, including the following conditions: presence of a local active ulcer lesion with fecal occult blood (++) making them ineligible for enrollment; history of melena or hematemesis within 2 months; presence of high bleeding risk: Grade ≥ 3 bleeding events within the past 6 months, hemoptysis ≥ 2.5 mL per episode; imaging suggesting tumor erosion into major blood vessels; or investigator judgment that the bleeding risk is unacceptable;
  15. Presence of high risk of gastrointestinal perforation/fistula: gastrointestinal perforation or active peptic ulcer within the past 6 months; or pelvic tumor significantly invading the bladder/rectum with potential risk of fistula (investigator judgment);
  16. Coagulation abnormalities (INR > 1.5, APTT > 1.5 × ULN) with a bleeding tendency;
  17. Long-term unhealed wounds or fractures; major surgery or severe traumatic injury, fracture, or ulcer within 4 weeks.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Mirvetuximab Soravtansine + Suvemcitug

Patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer will receive mirvetuximab soravtansine combined with suvemcitug. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or other protocol-specified discontinuation criteria.

Mirvetuximab soravtansine is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody linked to the maytansinoid DM4. It is administered intravenously in combination with suvemcitug for the treatment of patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer.

Suvemcitug is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). In this study, suvemcitug is administered intravenously in combination with mirvetuximab soravtansine to evaluate the efficacy and safety in patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall Response Rate(ORR)
大体时间:up to 24 months

Investigator-assessed ORR, including confirmed best overall response of CR or PR per RECIST v1.1.

up to 24 months

次要结果测量

结果测量
措施说明
大体时间
Progression-Free Survival(PFS)
大体时间:up to 24 months

Investigator-assessed PFS: Defined as the time from first dose to the first documented PD per tumor assessment follow-up or death from any cause (whichever occurs first).

up to 24 months
During of response*(DoR)
大体时间:up to 24 months

Investigator-assessed DOR: For patients who achieve an objective response, DOR is defined as the time from first meeting CR/PR criteria (whichever occurs first) to the date of PD or death from any cause (whichever occurs first).

up to 24 months
Overall Survival (OS)
大体时间:up to 24 months

OS: Defined as the time from first dose to death from any cause (for patients lost to follow-up prior to death, the last follow-up date is typically used as the date of death).

up to 24 months
CA125 response
大体时间:up to 24 months

CA125 response: Assessed according to GCIG (Gynecologic Cancer InterGroup) criteria.

In the GCIG CA125 criteria, CA125 response is defined as a reduction in CA125 level of at least 50% after treatment, maintained for at least 28 days. CA125 assessment can only be performed if the patient's CA125 level is greater than twice the upper limit of normal within the 2 weeks before the start of treatment.

up to 24 months
Incidence, severity, and duration of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs). (Assessed by the investigator per CTCAE criteria.)
大体时间:up to 24 months
up to 24 months
Incidence of Grade ≥3 treatment-related adverse events (TRAEs) assessed by the investigator. (Assessed by the investigator per CTCAE criteria.)
大体时间:up to 24 months
up to 24 months

其他结果措施

结果测量
大体时间
Correlation between baseline tumor tissue FRα expression levels and other exploratory biomarker characteristics with ORR, PFS, DOR, and treatment-related adverse events.
大体时间:up to 24 months
up to 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月10日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年6月30日

研究注册日期

首次提交

2026年11月6日

首先提交符合 QC 标准的

2026年11月6日

首次发布 (实际的)

2026年11月12日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅